Article
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral research - 1 Feb 2012
Margot Nicolas A, Hluhanich Rebecca M, Jones Gregg S, Andreatta Kristen N, Tsiang Manuel, McColl Damian J, White Kirsten L, Miller Michael D
Abstract excerpt
Elvitegravir is a strand transfer inhibitor of HIV-1 integrase that is currently undergoing phase 3 clinical testing. The two predominant metabolites of elvitegravir, M1 and M4 (elvitegravir hydroxide and elvitegravir glucuronide), have been shown to inhibit HIV-1 integrase in vitro. While they are markedly less potent than elvitegravir and present only at low levels in plasma clinically, we investigated their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
